Illuminating the molecular ,mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: The Achilles' heel of targeted therapy

ACS Chemical Biology

Volumn 10, Issue 5, 2015, Pages 1319-1329

  Sohl, Christal D ^a   Ryan, Molly R ^a   Luo, Beibei ^a   Frey, Kathleen M ^a   Anderson, Karen S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 4547; FIBROBLAST GROWTH FACTOR RECEPTOR 1; LUCITANIB; PROTEIN TYROSINE KINASE INHIBITOR; FGFR1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ARTICLE; AUTOPHOSPHORYLATION; BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; DRUG CONFORMATION; DRUG RECEPTOR BINDING; FGFR1 GENE; GENE AMPLIFICATION; GENE MUTATION; HYDROPHOBICITY; MOLECULAR STABILITY; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR GENE; SQUAMOUS CELL LUNG CARCINOMA; STRUCTURE ACTIVITY RELATION; WILD TYPE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG RESISTANCE; GENETICS; HUMAN; KINETICS; MOLECULAR MODEL; MUTATION; PHOSPHORYLATION; PROTEIN CONFORMATION;

PYRONIA TITHONUS;

DRUG RESISTANCE, NEOPLASM; HUMANS; KINETICS; MODELS, MOLECULAR; MUTATION; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1;

EID: 84929577575     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/acschembio.5b00014     Document Type: Article

References (52)

1. Turner, N. and Grose, R. (2010) Fibroblast growth factor signalling: from development to cancer Nat. Rev. Cancer 10, 116-129
2. Ahmad, I., Iwata, T., and Leung, H. Y. (2012) Mechanisms of FGFR-mediated carcinogenesis Biochim. Biophys. Acta 1823, 850-860
3. Lemmon, M. A. and Schlessinger, J. (2010) Cell signaling by receptor tyrosine kinases Cell 141, 1117-1134
4. Furdui, C. M., Lew, E. D., Schlessinger, J., and Anderson, K. S. (2006) Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction Mol. Cell 21, 711-717
5. Chen, H., Xu, C. F., Ma, J., Eliseenkova, A. V., Li, W., Pollock, P. M., Pitteloud, N., Miller, W. T., Neubert, T. A., and Mohammadi, M. (2008) A crystallographic snapshot of tyrosine trans-phosphorylation in action Proc. Natl. Acad. Sci. U.S.A. 105, 19660-19665
6. Tenhagen, M., van Diest, P. J., Ivanova, I. A., van der Wall, E., and van der Groep, P. (2012) Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets Endocr. Relat. Cancer 19, R115-R129
7. Lew, E. D., Furdui, C. M., Anderson, K. S., and Schlessinger, J. (2009) The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations Sci. Signal. 2, ra6
8. Greulich, H. and Pollock, P. M. (2011) Targeting mutant fibroblast growth factor receptors in cancer Trends Mol. Med. 17, 283-292
9. Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M. A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., Gillett, C., Grigoriadis, A., Tutt, A., Reis-Filho, J. S., and Ashworth, A. (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer Cancer Res. 70, 2085-2094
10. Dutt, A., Ramos, A. H., Hammerman, P. S., Mermel, C., Cho, J., Sharifnia, T., Chande, A., Tanaka, K. E., Stransky, N., Greulich, H., Gray, N. S., and Meyerson, M. (2011) Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer PLoS One 6, e20351
11. Gavine, P. R., Mooney, L., Kilgour, E., Thomas, A. P., Al-Kadhimi, K., Beck, S., Rooney, C., Coleman, T., Baker, D., Mellor, M. J., Brooks, A. N., and Klinowska, T. (2012) AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family Cancer Res. 72, 2045-2056
12. Huang, Z., Tan, L., Wang, H., Liu, Y., Blais, S., Deng, J., Neubert, T. A., Gray, N. S., Li, X., and Mohammadi, M. (2014) DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors ACS Chem. Biol. 10, 299-309
13. Mohammadi, M., Froum, S., Hamby, J. M., Schroeder, M. C., Panek, R. L., Lu, G. H., Eliseenkova, A. V., Green, D., Schlessinger, J., and Hubbard, S. R. (1998) Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain EMBO J. 17, 5896-5904
14. Klein, T., Tucker, J., Holdgate, G. A., Norman, R. A., and Breeze, A. L. (2014) FGFR1 kinase inhibitors: close regioisomers adopt divergent binding modes and display distinct biophysical signatures ACS Med. Chem. Lett. 5, 166-171
15. Norman, R. A., Schott, A. K., Andrews, D. M., Breed, J., Foote, K. M., Garner, A. P., Ogg, D., Orme, J. P., Pink, J. H., Roberts, K., Rudge, D. A., Thomas, A. P., and Leach, A. G. (2012) Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase J. Med. Chem. 55, 5003-5012
16. Ravindranathan, K. P., Mandiyan, V., Ekkati, A. R., Bae, J. H., Schlessinger, J., and Jorgensen, W. L. (2010) Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening J. Med. Chem. 53, 1662-1672
17. Tan, L., Wang, J., Tanizaki, J., Huang, Z., Aref, A. R., Rusan, M., Zhu, S. J., Zhang, Y., Ercan, D., Liao, R. G., Capelletti, M., Zhou, W., Hur, W., Kim, N., Sim, T., Gaudet, S., Barbie, D. A., Yeh, J. R., Yun, C. H., Hammerman, P. S., Mohammadi, M., Janne, P. A., and Gray, N. S. (2014) Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors Proc. Natl. Acad. Sci. U.S.A. 111, E4869-E4877
18. Bello, E., Colella, G., Scarlato, V., Oliva, P., Berndt, A., Valbusa, G., Serra, S. C., D'Incalci, M., Cavalletti, E., Giavazzi, R., Damia, G., and Camboni, G. (2011) E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models Cancer Res. 71, 1396-1405
19. Zhou, Y., Chen, Y., Tong, L., Xie, H., Wen, W., Zhang, J., Xi, Y., Shen, Y., Geng, M., Wang, Y., Jiang, H., Luo, C., Lin, L., and Ding, J. (2012) AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR J. Cell. Mol. Med. 16, 2321-2330
20. Soria, J. C., DeBraud, F., Bahleda, R., Adamo, B., Andre, F., Dientsmann, R., Delmonte, A., Cereda, R., Isaacson, J., Litten, J., Allen, A., Dubois, F., Saba, C., Robert, R., D'Incalci, M., Zucchetti, M., Camboni, M. G., and Tabernero, J. (2014) Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors Ann. Oncol. 25, 2244-2251
21. Zuccotto, F., Ardini, E., Casale, E., and Angiolini, M. (2010) Through the "gatekeeper door": exploiting the active kinase conformation J. Med. Chem. 53, 2681-2694
22. Azam, M., Seeliger, M. A., Gray, N. S., Kuriyan, J., and Daley, G. Q. (2008) Activation of tyrosine kinases by mutation of the gatekeeper threonine Nat. Struct. Mol. Biol. 15, 1109-1118
23. Johnson, L. N. (2009) Protein kinase inhibitors: contributions from structure to clinical compounds Q. Rev. Biophys. 42, 1-40
24. Bae, J. H., Lew, E. D., Yuzawa, S., Tome, F., Lax, I., and Schlessinger, J. (2009) The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site Cell 138, 514-524
25. Gibbons, D. L., Pricl, S., Kantarjian, H., Cortes, J., and Quintas-Cardama, A. (2012) The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm Cancer 118, 293-299
26. Ang, D., Ballard, M., Beadling, C., Warrick, A., Schilling, A., O'Gara, R., Pukay, M., Neff, T. L., West, R. B., Corless, C. L., and Troxell, M. L. (2014) Novel mutations in neuroendocrine carcinoma of the breast: possible therapeutic targets Diagn. Mol. Pathol. 10.1097/PDM.0b013e3182a40fd1
27. Byron, S. A., Chen, H., Wortmann, A., Loch, D., Gartside, M. G., Dehkhoda, F., Blais, S. P., Neubert, T. A., Mohammadi, M., and Pollock, P. M. (2013) The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors Neoplasia 15, 975-988
28. Chell, V., Balmanno, K., Little, A. S., Wilson, M., Andrews, S., Blockley, L., Hampson, M., Gavine, P. R., and Cook, S. J. (2013) Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance Oncogene 32, 3059-3070
29. Blencke, S., Zech, B., Engkvist, O., Greff, Z., Orfi, L., Horvath, Z., Keri, G., Ullrich, A., and Daub, H. (2004) Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors Chem. Biol. 11, 691-701
30. Oxnard, G. R., Arcila, M. E., Chmielecki, J., Ladanyi, M., Miller, V. A., and Pao, W. (2011) New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer Clin. Cancer Res. 17, 5530-5537
31. O'Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W. S., Xu, Q., Metcalf, C. A., III, Tyner, J. W., Loriaux, M. M., Corbin, A. S., Wardwell, S., Ning, Y., Keats, J. A., Wang, Y., Sundaramoorthi, R., Thomas, M., Zhou, D., Snodgrass, J., Commodore, L., Sawyer, T. K., Dalgarno, D. C., Deininger, M. W., Druker, B. J., and Clackson, T. (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance Cancer Cell 16, 401-412
32. Tucker, J. A., Klein, T., Breed, J., Breeze, A. L., Overman, R., Phillips, C., and Norman, R. A. (2014) Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4 Structure 22, 1764-1774
33. Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., Rettig, W. J., Meyerson, M., Solca, F., Greulich, H., and Wong, K. K. (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 27, 4702-4711
34. Gao, W., Wang, M., Wang, L., Lu, H., Wu, S., Dai, B., Ou, Z., Zhang, L., Heymach, J. V., Gold, K. A., Minna, J., Roth, J. A., Hofstetter, W. L., Swisher, S. G., and Fang, B. (2014) Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells J. Natl. Cancer Inst. 106, dju204
35. Das, K., Lewi, P. J., Hughes, S. H., and Arnold, E. (2005) Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors Prog. Biophys. Mol. Biol. 88, 209-231
36. Lansdon, E. B., Brendza, K. M., Hung, M., Wang, R., Mukund, S., Jin, D., Birkus, G., Kutty, N., and Liu, X. (2010) Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design J. Med. Chem. 53, 4295-4299
37. Mohammadi, M., Schlessinger, J., and Hubbard, S. R. (1996) Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism Cell 86, 577-587
38. Bae, J. H., Boggon, T. J., Tome, F., Mandiyan, V., Lax, I., and Schlessinger, J. (2010) Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells Proc. Natl. Acad. Sc.i USA 107, 2866-2871
39. Chen, H., Ma, J., Li, W., Eliseenkova, A. V., Xu, C., Neubert, T. A., Miller, W. T., and Mohammadi, M. (2007) A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases Mol. Cell 27, 717-730
40. Norman, R. A., Toader, D., and Ferguson, A. D. (2012) Structural approaches to obtain kinase selectivity Trends Pharmacol. Sci. 33, 273-278
41. Lin, Z., Jensen, J. K., Hong, Z., Shi, X., Hu, L., Andreasen, P. A., and Huang, M. (2013) Structural insight into inactivation of plasminogen activator inhibitor-1 by a small-molecule antagonist Chem. Biol. 20, 253-261
42. Dar, A. C., Lopez, M. S., and Shokat, K. M. (2008) Small molecule recognition of c-Src via the Imatinib-binding conformation Chem. Biol. 15, 1015-1022
43. Tsai, C. J. and Nussinov, R. (2014) The free energy landscape in translational science: how can somatic mutations result in constitutive oncogenic activation? Phys. Chem. Chem. Phys. 16, 6332-6341
44. Sutto, L. and Gervasio, F. L. (2013) Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase Proc. Natl. Acad. Sci. U.S.A. 110, 10616-10621
45. Taylor, S. S. and Kornev, A. P. (2011) Protein kinases: evolution of dynamic regulatory proteins Trends Biochem. Sci. 36, 65-77
46. Zhou, W., Hur, W., McDermott, U., Dutt, A., Xian, W., Ficarro, S. B., Zhang, J., Sharma, S. V., Brugge, J., Meyerson, M., Settleman, J., and Gray, N. S. (2010) A structure-guided approach to creating covalent FGFR inhibitors Chem. Biol. 17, 285-295
47. Zhang, J., Yang, P. L., and Gray, N. S. (2009) Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 9, 28-39
48. Wong, C. F. (2008) Flexible ligand-flexible protein docking in protein kinase systems Biochim. Biophys. Acta 1784, 244-251
49. Knight, Z. A., Lin, H., and Shokat, K. M. (2010) Targeting the cancer kinome through polypharmacology Nat. Rev. Cancer 10, 130-137
50. Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., and Peterson, J. R. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity Nat. Biotechnol. 29, 1039-1045
51. Minor, W., Cymborowski, M., Otwinowski, Z., and Chruszcz, M. (2006) HKL-3000: the integration of data reduction and structure solution - from diffraction images to an initial model in minutes Acta Crystallogr. D Biol. Crystallogr. 62, 859-866
52. Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr. D Biol. Crystallogr. 66, 213-221